At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,463 enrolled
Drug / intervention
Idalopirdine 60 mgdrug
Likely dose
Idalopirdine 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease
In Brief
A Phase 3 clinical trial evaluating Idalopirdine 60 mg for Alzheimer's Disease. Completed, enrolled 1,463 participants across 258 sites in 27 countries.
Detailed Summary
To evaluate the long-term safety and tolerability of idalopirdine (Lu AE58054) as adjunctive therapy to donepezil in patients with mild-moderate Alzheimer's Disease (AD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesArgentina, Belgium, Brazil, Bulgaria, Canada, Chile, Croatia, Czechia, Denmark, Estonia, Finland, France, Germany, Hungary, Israel, Italy, Lithuania, Poland, Portugal, Romania, South Africa, South Korea, Spain, Taiwan, Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 2014
Enrollment StartApr 2014
Primary CompletionJul 2017
TodayJul 2026
First PostedMar 5, 2014
Enrollment StartApr 7, 2014
Primary CompletionJul 6, 2017
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 12.3 years ago
Interventions
Idalopirdine 60 mgdrug
once daily, encapsulated tablets, orally